Scientists developed a method to produce a longer-lasting form of thymosin alpha-1 by fusing it with human serum albumin and adding a natural chemical modification called N-acetylation using the bacterial enzyme RimJ. The resulting modified fusion protein retained full biological activity and is expected to be a more effective pharmaceutical agent than standard thymosin alpha-1.
Chen, Jing; Li, Haibin; Wang, Tao; Sun, Shuyang; Liu, Jia; Chen, Jianhua